Metoject Methotrexate Injection 15mg 0.3ml

Metoject 15 mg / 0.3 ml is a solution for injection containing the active ingredient Methotrexate at a concentration of 50 mg/ml. It comes in a pre-filled syringe with a volume of 0.3 ml containing 15 mg of Methotrexate. Metoject is used under medical supervision to treat certain inflammatory and autoimmune diseases, particularly active rheumatoid arthritis, certain cases of psoriatic arthritis, and severe psoriasis, based on diagnosis and clinical response.

Indications for Use (Metoject 15 mg)

Methotrexate works by suppressing immune system activity and reducing inflammation. It is used to treat several inflammatory and autoimmune conditions, including:

• Active rheumatoid arthritis in adults.

• Severe, active forms of polyarticular juvenile idiopathic arthritis.

• Severe psoriasis that does not respond adequately to other therapies.

• Severe psoriatic arthritis.

How to Use Metoject

• Metoject is administered ONCE A WEEK ONLY, on the specific day assigned by your doctor, unless a different schedule is prescribed for your medical condition. It must never be taken daily, as using methotrexate more frequently than prescribed can lead to severe and life-threatening toxicity.

• Metoject is administered via subcutaneous injection (under the skin). Common injection sites include the abdominal area (away from the navel) or the upper thigh, following the directions of your doctor or healthcare provider.

• Strictly adhere to the prescribed dose and schedule. Do not alter the dosage or injection frequency without consulting your doctor.

Possible Side Effects

Metoject may cause side effects, which vary in severity from person to person. These may include:

• Nausea or vomiting

• Loss of appetite

• Abdominal pain or gastrointestinal discomfort

• Mouth ulcers (stomatitis)

• Headache or fatigue

• Elevated liver enzymes

• Decreased blood cell counts

Serious Side Effects:

More severe complications can occur, such as bone marrow suppression, liver or kidney impairment, severe infections, or methotrexate-induced lung injury (pneumonitis). Therefore, treatment requires ongoing medical oversight and periodic laboratory monitoring as directed by your physician.

Seek immediate medical attention if you experience: Shortness of breath, persistent cough, fever, unusual bleeding or bruising, or yellowing of the skin or eyes (jaundice).

Precautions and Warnings

• Metoject must be used under specialized medical supervision and is available by prescription only.

• Inform your doctor before starting treatment if you have a history of liver or kidney disease, blood disorders, active infections, or lung disease.

• Pregnancy Warning: Methotrexate is strictly contraindicated during pregnancy due to the risk of fetal harm. Pregnancy must be avoided during treatment, and effective contraception must be maintained for the period specified by your doctor following discontinuation.

• Inform your doctor or pharmacist of all medications and dietary supplements you are taking, as methotrexate interacts with various drugs, which may require dosage adjustments or intensified monitoring.

Storage Instructions

• Store below 25°C.

• Do not freeze.

• Keep the pre-filled syringe inside its outer carton to protect it from light.

• Keep out of reach of children.

• Dispose of used syringes in a designated sharp disposal container following safe disposal guidelines.

Note: Metoject is a prescription-only medication that requires regular clinical and laboratory monitoring. Do not initiate therapy, adjust doses, or alter the injection schedule on your own.

Ingredients

• Active Ingredient: Methotrexate 15 mg / 0.3 ml

Frequently Asked Questions (FAQ)

Is Metoject considered chemotherapy?

The active ingredient, Methotrexate, is also used in certain cancer treatment protocols; however, the dosage, administration schedule, and therapeutic objectives are completely different. When Metoject is administered in low, once-weekly doses for arthritis and inflammatory conditions, it functions as a Disease-Modifying Antirheumatic Drug (DMARD) and immunosuppressant—not at the high-dose chemotherapeutic regimens used for malignancy.